HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 28, 2015--
First paragraph, second sentence of release dated September 23, 2015,
should read: The presentation will take place at 2:00 pm EDT on Tuesday,
September 29 at the Sofitel Hotel in New York City (instead of: The
presentation will take place at 2:30 pm EDT on Tuesday, September 29 at
the Sofitel Hotel in New York City).
The corrected release reads:
vTv THERAPEUTICS TO PRESENT AT LADENBURG THALMANN 2015 HEALTHCARE
CONFERENCE
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical
company engaged in the discovery and development of new orally
administered treatments for Alzheimer’s disease and diabetes, today
announced that Stephen Holcombe, President and CEO, and Aaron Burstein,
SVP, Clinical Development, will be presenting a corporate overview at
the Ladenburg Thalmann 2015 Healthcare Conference. The presentation will
take place at 2:00 pm EDT on Tuesday, September 29 at the Sofitel Hotel
in New York City.
A live webcast of the presentation can be accessed on the News
& Events section of the website. The webcast will be archived
for 30 days following the presentation on the company website at www.vtvtherapeutics.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of orally administered small
molecule drug candidates to fill significant unmet medical needs. vTv
has a pipeline of clinical drug candidates led by programs for the
treatment of Alzheimer’s disease and type 2 diabetes as well as
treatment of inflammatory disorders and the prevention of muscle
weakness.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150923005380/en/
Source: vTv Therapeutics Inc.
vTv Therapeutics Inc.
Investors
The Trout Group
Marc
Panoff, 646-378-2958
mpanoff@troutgroup.com
or
Media
BMC
Communications
Brad Miles, 646-513-3125
bmiles@bmccommunications.com
